273 related articles for article (PubMed ID: 30052597)
21. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 18 F-AlF-NOTA-PRGD2 and 18 F-FDG PET/CT Imaging in a Case of Primary Uveal Melanoma.
Zhu X; Pan D; Zhang Z; Wang K; Zou W
Clin Nucl Med; 2024 May; 49(5):489-490. PubMed ID: 38465994
[TBL] [Abstract][Full Text] [Related]
24. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.
Cleary JO; Yeung J; McMeekin H; Wilhelm T; Wagner T
Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848
[TBL] [Abstract][Full Text] [Related]
25. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report.
Xiangsong Z; Xingchong S; Chang Y; Xiaoyan W; Zhifeng C
Clin Nucl Med; 2011 Nov; 36(11):1003-6. PubMed ID: 21975388
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin αvβ3.
Zheng Y; Wang H; Tan H; Cui X; Yao S; Zang J; Zhang L; Zhu Z
Clin Nucl Med; 2019 Sep; 44(9):687-694. PubMed ID: 31274560
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of Brain Incidental Lesions Detected by
Albano D; Treglia G; Dondi F; Bertagna F
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888635
[No Abstract] [Full Text] [Related]
29. Prospective Study of (68)Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients.
Wang Z; Zhang M; Wang L; Wang S; Kang F; Li G; Jacobson O; Niu G; Yang W; Wang J; Chen X
Theranostics; 2015; 5(8):882-9. PubMed ID: 26000059
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
Chung JK; Kim YK; Kim SK; Lee YJ; Paek S; Yeo JS; Jeong JM; Lee DS; Jung HW; Lee MC
Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):176-82. PubMed ID: 11926379
[TBL] [Abstract][Full Text] [Related]
31. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery.
Liu RS; Chang CP; Guo WY; Pan DH; Ho DM; Chang CW; Yang BH; Wu LC; Yeh SH
J Nucl Med; 2010 Jun; 51(6):883-91. PubMed ID: 20484430
[TBL] [Abstract][Full Text] [Related]
32. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
33. Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke.
Sun Y; Zeng Y; Zhu Y; Feng F; Xu W; Wu C; Xing B; Zhang W; Wu P; Cui L; Wang R; Li F; Chen X; Zhu Z
Theranostics; 2014; 4(8):778-86. PubMed ID: 24955139
[TBL] [Abstract][Full Text] [Related]
34. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
35.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
36. [
Lawal IO; Popoola GO; Mahapane J; Kaufmann J; Davis C; Ndlovu H; Maserumule LC; Mokoala KMG; Bouterfa H; Wester HJ; Zeevaart JR; Sathekge MM
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287237
[TBL] [Abstract][Full Text] [Related]
37. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
38.
Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
[TBL] [Abstract][Full Text] [Related]
39. 68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases.
Unterrainer M; Ruf V; Ilhan H; Vettermann FJ; Cyran CC; Niyazi M; Bartenstein P; Tonn JC; Albert NL
Clin Nucl Med; 2019 May; 44(5):412-413. PubMed ID: 30829858
[TBL] [Abstract][Full Text] [Related]
40. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
